Next-Generation Peptides: AI-driven approaches for peptide therapeutics beyond the natural repertoire
Doctoral thesis, 2026

Peptides are becoming an attractive modality in drug discovery as they sit in the intersection of small molecules and proteins. They combine advantages drawn from both modalities such as high specificity, low immunogenicity typically associated with protein therapeutics, and good efficacy, potential for membrane permeability more common to small molecules. Nevertheless, they demand an exhaustive search for an optimal amino acid sequence to meet a multi-objective profile including metabolic stability, solubility, and potency needed for becoming a standalone drug. Essential aspect of property optimization is incorporating non-natural amino acids (NNAAs) to peptides, generally to enhance their permeability and affinity. However, design make-test-analyze (DMTA) cycles often rely on trial‑and‑error of positional mutations. This makes the identification of peptides meeting the design goals exhaustive and time‑consuming. Drug discovery pipelines are accelerated by the recent surge of artificial intelligence (AI)-driven technologies for small molecules and proteins. This thesis presents in silico tools that facilitate drug design by extending AI-based methodologies to peptide therapeutics. The solutions presented here enable designs beyond the natural amino acids while allowing efficient exploration of the chemical space that is expanded by novel and diverse NNAAs. This includes developing AI-driven methodologies for design, evaluation, and optimization of next-generation therapeutic peptides. To design peptides, a chemistry-aware generative model was built to incorporate NNAAs into user-defined positions of a given starting peptide. This model is guided by reinforcement learning feedback to iteratively optimize designs for desired properties such as permeability and solubility. This design process is supplemented by a series of methodologies to evaluate the generated designs. First, peptide-specific predictive models that leverage model uncertainty were developed to efficiently predict permeability and steer design decisions toward reliable property space. Second, an NNAA synthesis assistance tool was proposed. This tool evaluates the chemical synthesizability of amino acids by considering protection strategies required for peptide synthesis and adapts predictive models for small molecule retrosynthesis and synthetic feasibility to peptide building blocks. Collectively, studies presented in this thesis develop cheminformatics and AI applications to design novel, synthesizable and pharmacologically relevant peptides while expanding the chemical space accessible to peptide drug discovery.

reinforcement learning

non-natural amino acids

peptide design

drug discovery

predictive models

uncertainty quantification

synthetic feasibility

generative AI

Hall KB, Chemistry Building, Chalmers Campus Johanneberg, Gothenburg
Opponent: Ewa Szczurek, Associate Professor, University of Warsaw / Institute AI for Health, Helmholtz Zentrum München

Author

Gökçe Geylan

Chalmers, Life Sciences, Systems and Synthetic Biology

PepINVENT: generative peptide design beyond natural amino acids

Chemical Science,;Vol. 16(2025)p. 8682-8696

Journal article

van Weesep, L., Chankeshwara, S., De Maria, L., David, F., Engkvist, O., Geylan, G. Conformal Prediction Enhances the Efficiency of Designing Permeable Peptides in Reinforcement Learning-Guided Optimization

Designing New Medicines Beyond Nature’s Alphabet Using AI
Peptides, short chains of amino acids, are promising drug candidates that can reach biological targets that traditional drugs struggle to access. Turning peptides into drugs, however, requires a long search for an optimal amino acid sequence among all possible combinations. Furthermore, the amino acids found in nature present a limit to balance the properties required to make a drug-like peptide. Therefore, non-natural amino acids (NNAAs) have been included in the peptide designers’ trial-and-error experiments in the quest of finding the “perfect” peptides. Evaluating every single peptide is costly and exhausting, but artificial intelligence (AI) can help find the ones with desired properties by searching the peptide universe efficiently. This thesis brings complementary AI tools together to make peptide design faster, more reliable and more practicable in the lab. First, I have developed an AI tool that serves as an idea engine for peptide designs with a smart exploration of the peptide space. The tool suggests peptides containing amino acids that extend beyond nature’s building blocks. This enables tailor fit designs that are specific for therapeutic objectives. Second, I focused on cell membrane permeability of peptides, an essential property for reaching most of the drug targets. Methodologies on how to predict cell membrane permeability of peptides with confidence were established and used in ideation. Lastly, it’s not enough to find the optimal sequences on a computer since researchers also need to be able to make them. Therefore, an AI-driven workflow to help prioritize the designs that can be synthesized was created. The research illustrates how AI can be used to explore the vast space of peptides, to propose new and reliable designs, that are synthetically accessible.

AI-guidad design för cykliska peptidläkemedel

Swedish Foundation for Strategic Research (SSF) (ID20-0109), 2021-01-01 -- 2025-01-01.

Subject Categories (SSIF 2025)

Molecular Biology

Pharmaceutical Sciences

Artificial Intelligence

Driving Forces

Sustainable development

Innovation and entrepreneurship

Roots

Basic sciences

Areas of Advance

Life Science Engineering (2010-2018)

DOI

10.63959/chalmers.dt/5824

ISBN

978-91-8103-367-0

Doktorsavhandlingar vid Chalmers tekniska högskola. Ny serie: 5824

Publisher

Chalmers

Hall KB, Chemistry Building, Chalmers Campus Johanneberg, Gothenburg

Online

Opponent: Ewa Szczurek, Associate Professor, University of Warsaw / Institute AI for Health, Helmholtz Zentrum München

More information

Latest update

2/25/2026